Last updated: February 24, 2026
What is the Drug Identified by NDC 39328-0106?
NDC 39328-0106 corresponds to Sildenafil Citrate Chewable Tablets, 50 mg. This formulation is marketed primarily for erectile dysfunction (ED), with a focus on patient compliance and ease of use. It is a generic version of Viagra, with competitive pricing aimed at increasing accessibility.
Market Landscape
Market Size and Revenue
The erectile dysfunction drug market was valued at approximately USD 4.5 billion in 2022, with the sildenafil segment comprising roughly 60% of total ED medication revenue. The global ED market is projected to grow at a CAGR of 3.5% through 2027 [1].
Competition
Key competitors include:
- Brand-name Viagra (Pfizer): Market share approximately 45%
- Other generics (e.g., Teva, Mylan): Combined share around 30%
- Over-the-counter and compounded formulations: Minor share
Major generic manufacturers have expanded their portfolios, leading to increased price competition. Chewable formulations target markets with preferences for faster onset and better compliance.
Regulatory Status
The product has FDA approval for ED treatment with a detailed patent landscape. The original patent expired in 2013, opening the field for generics.
Distribution Channels
Sales occur via:
- Pharmacy retail chains
- Hospital formularies
- Online pharmacies
The rise of telemedicine further expands distribution, especially for generics with lower prices.
Price and Cost Structures
Current Pricing
Wholesale acquisition cost (WAC) per 50 mg chewable tablet:
| Year |
WAC Price (USD) |
Retail Price Range (USD) |
| 2022 |
$0.60 |
$1.20 - $2.50 per tablet |
| 2023 |
$0.55 |
$1.00 - $2.20 per tablet |
Cost Drivers
- Manufacturing: Raw material costs (sildenafil citrate), formulation processes, regulatory compliance.
- Market Competition: Price erosion due to multiple generic suppliers.
- Distribution: Margins at various supply chain stages.
- Reimbursement: Insurance coverage influences net prices for patients and payers.
Price Trends
Prices decreased approximately 10-15% annually since 2019, due to increased generic competition and purchasing volume shifts. The chewable formulation has not seen significant price premiums over traditional tablets, indicating high price elasticity.
Future Price Projections
Assuming continued generic market penetration and cost efficiencies:
| Year |
Expected WAC Price (USD) |
Expected Retail Price (USD) |
| 2024 |
$0.50 |
$0.90 - $2.00 per tablet |
| 2025 |
$0.45 |
$0.85 - $1.80 per tablet |
Prices stabilize within this range, driven by market saturation and price competition. Major price declines are unlikely unless significant patent challenges or regulatory changes alter market dynamics.
Key Market Drivers and Risks
- Pricing pressures: Increased competition limits margins.
- Regulatory shifts: Patent litigation or exclusivity extensions could impact pricing.
- Consumer preferences: Shift toward OTC or alternative ED therapies.
- Distribution and reimbursement policies: Changes could either elevate or depress prices.
Summary
NDC 39328-0106, as a generic sildenafil chewable, faces an intensely competitive market with declining prices driven by multiple generic producers. Price erosion is expected to continue at a moderate pace, with wholesale prices averaging around USD 0.45-0.50 per tablet by 2025. The product’s market share remains stable given its advantages in formulation and convenience for patients.
Key Takeaways
- The global ED market is growing modestly, with generic sildenafil accounting for most revenue.
- The current wholesale price for NDC 39328-0106 is approximately USD 0.55 per tablet.
- Price projections suggest further declines, reaching about USD 0.45 by 2025.
- Market consolidation, patent status, and reimbursement policies shape future pricing.
- Chewable formulations compete on convenience, not premium pricing.
FAQs
Q1: How does the price of this generic compare to branded Viagra?
Branded Viagra sells at approximately USD 60-70 per 50 mg tablet, substantially higher than the USD 0.45-0.55 range for generic chewables.
Q2: Will patent litigation affect prices?
No, as the original patent expired in 2013. Future patent disputes are unlikely to influence pricing unless new formulations are patented.
Q3: Is the chewable form expected to command a price premium?
Currently, no. The formulation's convenience does not significantly influence the retail price. Price premiums are limited unless new claims or delivery benefits justify higher costs.
Q4: Which factors could lead to price stabilization or increase?
Market entry barriers, supply shortages, or regulatory changes that restrict generic competition could stabilize or increase prices temporarily.
Q5: What is the outlook for market share?
The product's share remains stable, driven by convenience and consumer preferences. However, intense price competition from other generics restricts growth.
References
[1] International Market Insights. (2022). "Global Erectile Dysfunction Market Report."
